drugset / Trial / NCT04914936

A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196

NCT04914936

Phase 1 Completed 72 enrolled Acerta Pharma BV
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study will evaluate one-way interaction of calcium carbonate, omeprazole, or rifampin on ACP-196.

Timeline

Start
2014-09-21
Primary completion
2014-10-16
Completion
2014-10-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule 100 mg Oral
Subject Calcium carbonate Other / unclassified 1 g Oral
Subject Omeprazole Other / unclassified 40 mg Oral
Subject Rifampin Small molecule 600 mg Oral

Indications

No indication recorded.